Phio Pharmaceuticals Surges 6.76% to Monthly High on Clinical Data Presentation and Award Recognition

The share price rose to its highest level this month today, with an intraday gain of 6.76%.

Phio Pharmaceuticals (NASDAQ: PHIO) climbed on the back of two pivotal announcements. The company revealed it will present Phase 1b clinical trial data for its lead siRNA therapy, INTASYL PH-762, at the SITC 2025 conference on November 8. The trial evaluates the treatment’s safety and efficacy in addressing cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma. Separately, PH-762 was named “Immunomodulatory Solution of the Year” by the BioTech Breakthrough Awards, underscoring its potential as a non-surgical alternative to existing therapies.

Analysts highlighted the dual impact of clinical progress and industry validation. The SITC presentation offers a critical update on PH-762’s tolerability and biomarker activity, which could reinforce its pipeline momentum. The award, meanwhile, positions PH-762 as a differentiated therapy in a competitive oncology landscape, leveraging its localized PD-1 silencing mechanism to reduce systemic toxicity. With Phio’s valuation tied to near-term milestones, the stock’s rally reflects investor optimism about the drug’s ability to address unmet needs in skin cancer treatment and attract strategic partnerships.